Literature DB >> 32953578

Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Xing-Wang Chen1, Fang-Yuan Han2, Gang Su1, Le Pan1, Shan-Jun Cai3.   

Abstract

AIM: To observe choroidal thickness changes in the choroidal hyperpermeability area (CHA) in patients with central serous chorioretinopathy (CSC) after photodynamic therapy (PDT) using indocyanine green angiography (ICGA) combined with optical coherence tomography (OCT).
METHODS: This was a cohort study of 17 eyes (17 patients) with CSC. In all patients, the range of CHA was determined by ICGA. The patients were divided into two groups based on CHA covered the fovea (group A) or not (group B). All patients received half-dose verteporfin PDT over CHA in ICGA. Choroidal thickness was measured by OCT before, 1, and 3mo after treatment. The choroidal thickness values of the fovea and CHAs were obtained for each measurement. Secondary outcomes were changes in the best-corrected visual acuity (BCVA) and amount of subretinal fluid (SRF).
RESULTS: The differences in center choroidal thickness at baseline and at 1 and 3mo post-PDT were statistically significant in group A and all patients (both P<0.001). There was no significant difference in group B (P=0.059). The differences of thickness of CHA and BCVA at baseline and 1 and 3mo post-PDT were statistically significant in group A, group B, and all patients (all P<0.01). All patients showed complete SRF absorption at 3mo post-PDT.
CONCLUSION: Center choroidal thickness does not accurately reflect changes in CHA of patients whose CHA does not covered the fovea center. Using CHA as the observation target can make up for this limitation, expand the scope of application, and reduce bias. International Journal of Ophthalmology Press.

Entities:  

Keywords:  central serous chorioretinopathy; choroidal hyperpermeability; choroidal thickness; indocyanine green angiography; optical coherence tomography

Year:  2020        PMID: 32953578      PMCID: PMC7459213          DOI: 10.18240/ijo.2020.09.10

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  23 in total

1.  The long-term outcome of central serous chorioretinopathy.

Authors:  E Y Yap; D M Robertson
Journal:  Arch Ophthalmol       Date:  1996-06

2.  Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.

Authors:  L Hua; B Lin; J Hong; H-B Min; W-L Han; T-Y Zhou; Z-Q Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-01       Impact factor: 3.507

3.  Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.

Authors:  A Rabiolo; I Zucchiatti; A Marchese; G Baldin; R Sacconi; D Montorio; M V Cicinelli; L Querques; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2017-12-21       Impact factor: 3.775

4.  Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy.

Authors:  Takahiko Izumi; Hideki Koizumi; Ichiro Maruko; Yohei Takahashi; Shozo Sonoda; Taiji Sakamoto; Tomohiro Iida
Journal:  Br J Ophthalmol       Date:  2016-07-07       Impact factor: 4.638

Review 5.  Central Serous Chorioretinopathy Treatments: A Mini Review.

Authors:  Pierluigi Iacono; Maurizio Battaglia Parodi; Bruno Falcomatà; Francesco Bandello
Journal:  Ophthalmic Res       Date:  2015-12-01       Impact factor: 2.892

6.  Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin.

Authors:  Ming-Wei Zhao; Peng Zhou; Hong-Xiang Xiao; Yong-Shun Lv; Chun-An Li; Guo-Dong Liu; Xiao-Xin Li
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

7.  Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Wan-Leong Chan; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

8.  Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.

Authors:  Jun Woong Moon; Hyeong Gon Yu; Tae Wan Kim; Hyung Chan Kim; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

9.  Long-term follow-up of central serous chorioretinopathy.

Authors:  C M Gilbert; S L Owens; P D Smith; S L Fine
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

10.  Corticosteroids and central serous chorioretinopathy.

Authors:  Cynthia A Carvalho-Recchia; Lawrence A Yannuzzi; Silvana Negrão; Richard F Spaide; K Bailey Freund; Hanna Rodriguez-Coleman; Marcio Lenharo; Tomohiro Iida
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

View more
  1 in total

Review 1.  Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review.

Authors:  Alice Verticchio Vercellin; Alon Harris; Ari M Stoner; Francesco Oddone; Kristen Ann Mendoza; Brent Siesky
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.